Exchange: NASDAQ·Updated 07:04 AM EDT

GH News

News
all
press releases
Cathie Wood's ARK Invest Buys AVAV Stock Again, Trims GOOGL Stake And Sells Iridium
Cathie Wood's ARK Invest bought another 9,037 AeroVironment shares Tuesday, extending its AVAV buying to a second consecutive session.
Stocktwits
More News
Guardant Healths Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening (CRC) will be covered in EviCore by Evernorth clinical guidelines effective January 1, 2027, per ACS guidelines. EviCore is a Cigna-owned company and the...
Business Wire
Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 20 abstractsincluding one mini oral presentationshowcasing advances in methylation-based tumor classification and liquid biopsy technology across...
Business Wire
Business Insider Names Guardant Health One of America's Most Innovative Businesses
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has been named to Business Insiders America's Most Innovative Businesses 2027 list, earning the highest rating available with a five-star recognition awarded to only other 12 biotechnology research...
Business Wire
Guardant Health Announces Landmark FDA Approval of Guardant360 CDx as Companion Diagnostic for AstraZenecas ETCAMAH (camizestrant) in Advanced Breast Cancer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic (CDx) to identify patients with hormone receptor (HR)-positive, HER2-negative advanced or metastatic...
Business Wire
Guardant Healths Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening (CRC) will be covered in Carelon Healthcare Services clinical guidelines effective November 15. Carelon Healthcare Services is one of the largest specialty...
Business Wire
VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity?
Veracyte's 25.3% sell-off improves the entry price as strong core test demand and earnings growth face valuation, reimbursement and launch risks.
Zacks
Guardant Health to Appeal Federal District Court Judgment
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of...
Business Wire
Guardant Health Hit With Ongoing Royalties Over Duplex Sequencing Tech
Guardant Health must pay TwinStrand Biosciences and the University of Washington over $245 million after a court finalized a patent dispute.read more...
Benzinga
Tempus AI's FDA Win Could Unlock Major Reimbursement Growth Ahead
TEM's FDA approval for xT could unlock $85 million in annual revenue from higher pricing, with bigger gains tied to xF.
Zacks

Advertisement|Remove ads.